| 1.24 0.22 (21.57%) | 03-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.46 |
1-year : | 1.7 |
| Resists | First : | 1.25 |
Second : | 1.46 |
| Pivot price | 0.98 |
|||
| Supports | First : | 0.95 |
Second : | 0.76 |
| MAs | MA(5) : | 1.06 |
MA(20) : | 0.95 |
| MA(100) : | 1.14  |
MA(250) : | 1.12 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 82 |
D(3) : | 77 |
| RSI | RSI(14): 67.2 |
|||
| 52-week | High : | 2.34 | Low : | 0.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ALLR ] has closed above the upper band by 17.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 17.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.25 - 1.26 | 1.26 - 1.26 |
| Low: | 0.98 - 0.98 | 0.98 - 0.99 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Fri, 06 Mar 2026
Allarity Therapeutics Secures $20.9M Notes Financing From Streeterville, With Collateral Agreements - TradingView
Fri, 06 Mar 2026
Ovarian cancer drug keeping patients 30+ months gets $20M boost - Stock Titan
Wed, 18 Feb 2026
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - Yahoo Finance
Wed, 18 Feb 2026
VA lung cancer trial tests new drug combo for patients with few options - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 8 (%) |
| Shares Short | 216 (K) |
| Shares Short P.Month | 220 (K) |
| EPS | 9.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.7 % |
| Return on Equity (ttm) | -122.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | 0.13 |
| PEG Ratio | 0 |
| Price to Book value | 1.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|